Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck dulera (mometasone/formoterol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, Q4 2018
58
Period ended Dec 31, 2018
Change on a year earlier
-17.1%
70 in Q4 2017
History
8 quarters
Since Q1 2017
Sources
4
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2018 | Dec 31, 2018 | 58 | -17.1% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 44 | -15.4% | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | 35 | -44.4% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 50 | -33.3% | Form 10-Q (filed 2018-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 70 | – | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 52 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 63 | – | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 75 | – | Form 10-Q (filed 2018-05-08) ↗ |
Cite this data
StockData. (2026). Merck Dulera (mometasone/formoterol, legacy pre-Organon spin-off) — U.S. sales ($M) ($M), quarterly Q1 2017–Q4 2018 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_dulera_us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.